# Lung Cancer Screening: current status, guidelines and oportunities **David Strong, PhD**

**UC San Diego June 2023** 

UC San Diego **MOORES CANCER CENTER** 

### UC San Diego

Herbert Wertheim School of Public Health and Human Longevity Science



## Impact of Lung Cancer is Uneven Disparities in Tobacco Related Disease

- California has led the nation in reducing tobacco use, particularly among younger age groups
- In the 1970's California did not have the advantage of lower initiation, lower intensity of smoking and higher cessation and lung cancer mortality was higher than in the rest of the US.
- Reductions in tobacco use over the past 20 years has led to a difference in lung cancer mortality in California compared to the rest of the United States
- Reductions in tobacco use and incidence of lung cancer vary across communities.

Pierce et. Al., Cancer Prev Res; 12(1) January 2019

#### Goal





**Strategies** 

# **Prevention: Tobacco Control California vs Rest of United States**



Pierce et. Al., Cancer Prev Res; 12(1) January 2019

### **Prevention: Impact on Smoking is Uneven**

#### Prevalence Varies Greatly In San Diego



https://chronicdata.cdc.gov/500-Cities-Places/PLACES-Local-Data-for-Better-Health-Census-Tract-D

#### Prevalence Higher In Communities With Higher Rates of the Uninsured

![](_page_4_Figure_5.jpeg)

![](_page_4_Picture_7.jpeg)

### **Prevention: Impact on Lung Cancer is Uneven**

### Incidence Rates of Lung Cancer In California Vary By Race/Ethnicity, Region, and Sex

#### **Age-Adjusted Incidence Rate**

![](_page_5_Figure_3.jpeg)

DeRouen MC, Hu L, McKinley M, Gali K, Patel M, et al. (2018) Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California. PLOS ONE 13(5): e0197146. https://doi.org/10.1371/journal.pone.0197146 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197146

https://www.lung.org/research/state-of-lung-cancer/states/california tps://www.californiahealthmaps.org

![](_page_5_Figure_6.jpeg)

Rates of Lung Cancer For Women and Men Living In San Diego County

![](_page_5_Figure_8.jpeg)

### **Identifying Those At Risk** Health Systems Designed For Universal Screening For Tobacco Use

![](_page_6_Figure_1.jpeg)

Screening For Tobacco Use Status

![](_page_6_Figure_3.jpeg)

# Lung Cancer Screening

#### **California vs Rest of United States**

- Annual low-dose CT scans among those at high risk can reduce the lung cancer death rate by up to 20%
- California was one of the 46 states whose Medicaid fee-for-service programs covered lung cancer screening as of July 2022. Did not require prior authorization or copays.
- California ranked 51<sup>rst</sup> and screened 1% of those identified as at-risk.

![](_page_7_Figure_8.jpeg)

# UC Lung Cancer Consortium

### **All UC Health Systems**

- UC's five Cancer Centers
- Organized to improve lung cancer screening and treatment in California
- Develop UC-wide EPIC reports and data sharing
- Develop public-facing informational resources
- Promote coordinated improvements in care with groups targeting population health/policy and screening/prevention.

![](_page_8_Picture_7.jpeg)

![](_page_8_Picture_8.jpeg)

![](_page_8_Picture_9.jpeg)

### UC San Diego

![](_page_8_Picture_11.jpeg)

University of California San Francisco

![](_page_8_Picture_13.jpeg)

# Lung Cancer Screening Guidelines US Prevention Task Force

- Seven randomized clinical trials (RCTs) evaluated LDCT; the National Lung Screening Trial (NLST, N = 53454) and Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON, N = 15792) were the largest.
- The rate of positive screening tests in NLST was 24.2% with low-dose CT and 6.9% with radiography over all three rounds.
- Lung Cancer Mortality reduced for LDCT by ~20% in both NLST (IRR 0.85 [95% CI, 0.75-0.96]) and NELSON (IRR, 0.75 [95% CI, 0.61-0.90] trials relative to radiography.
- Harms of screening included false-positive results (26.3%) leading to unnecessary tests and invasive procedures (1.7%), incidental findings, and increases in distress.
- Guidelines for screening: Age 50-80; 20+ pack years; Current Smoker (quit <15years)
  - Shared Decision Making (with 1+ aid: benefits, harms, etc..)
  - Counseling to adhere to annual LDCT
  - Counseling to Engage Tobacco treatment

Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(10):971-987. doi:10.1001/jama.2021.0377

## **Screening Those At Risk** Health Systems Facilitate Referral to LDCT

![](_page_10_Figure_1.jpeg)

# Lung Cancer Treatment

![](_page_11_Figure_1.jpeg)

**JS States** 

#### **California vs Rest of United States**

- treatment.

https://www.lung.org/research/state-of-lung-cancer/states/california

 California ranked 46th with 26% of lung cancer cases not receiving

 California ranked 13th with 22% of cases undergoing surgery as part of the first course of treatment.

Massachusetts New York -Rhode Island -New Jersey -Connecticut -New Hampshire Maryland Maine Utah Colorado Pennsylvania Wisconsin Nebraska California District of Columbia Oregon Minnesota Illinois Nation Washington Florida Virginia · Ohio · States Delaware Montana Kentucky SU West Virginia Vermont North Carolina Michigan Idaho Tennessee Georgia South Carolina Hawaii Missouri North Dakota Alabama Louisiana Alaska lowa Indiana Mississippi Arkansas Arizona Texas South Dakota · Wyoming -Oklahoma · New Mexico -20% 0% 10% Percent of Cases Who Were

Treated with Surgery

![](_page_11_Picture_9.jpeg)

### **Tobacco Treatment For Patients With Cancer**

#### **Stopping Tobacco Improves Cancer Outcomes**

- In this cohort of patients with Non-Small Cell Lung Cancer, quitting smoking early in life was associated with reduced mortality following a lung cancer diagnosis.
- Surgeon General's Report details the reduced risk of recurrence and improved treatment outcomes across multiple cancer types for stopping tobacco, even after cancer diagnosis.

![](_page_12_Figure_4.jpeg)

No. at risk	
Never smokers	795
Former smokers	3269 2
Current smokers	1482

Overall Survival Among Patients With Non–Small Cell Lung Cancer (NSCLC) by Smoking Status at DiagnosisGraphs show survival among all patients with NSCLC (A),

From: Prediagnosis Smoking Cessation and Overall Survival Among Patients With Non–Small Cell Lung Cancer; JAMA Netw Open. 2023;6(5):e2311966

![](_page_12_Picture_10.jpeg)

![](_page_12_Picture_11.jpeg)

### **Tobacco Treatment: NCI Supported Efforts** Funding Improvements In Lung Cancer Outcomes

- (2015).
- Along with VA there are 8 clinical trials nearly finished.
- federal agencies to commit to promoting tobacco treatments.
- ulletApplications on July 1, 2023.

• NCI committed funds to an RFA to improve tobacco treatments during lung cancer screening

SCALE Collaboration (Smoking Cessation within the Context of Lung Cancer Screening).

• NCI Cancer Center Cessation Initiative (C3i): 52 cancer centers. Ongoing projects to improve tobacco treatment for all cancer patients, including those receiving lung cancer screening.

• White House Cancer Moonshot: Cessation Forum including CDC, HHS, FDA, VA and other

TRDRP will support research into the causes, early detection, and effective treatment, care, prevention, and potential cures of cancers. TRDRP expects to release the 2024 Call for

![](_page_13_Picture_11.jpeg)

## **Research and Implementation Projects Opportunities to Improve Locally and Statewide**

- screening and reviewing health systems workflow to reduce disparities.
- Treating Cases: understanding reluctance, barriers to access, patient-provider interactions, resources needed to deliver care and access surgical teams.

• *Prevention*: Tobacco use still prevalent in some communities and efforts to prevent initiation, understand new product use and promote tobacco treatment are needed.

• Identifying Those At Risk: campaigns to increase awareness to promote seeking

• Screening Those At Risk: understand barriers to accepting referrals, barriers to imaging, appeal of tobacco treatments (timing-modality-access), workflows to facilitate completion and return for follow-up screens, weigh benefits and harms in diverse community settings, biomarkers/technology to reduce false-positives.